Biotechs Tripling at IPO! Sign of Biotech Bubble?

The proverbial biotech IPO window has been open for some time now, but it appears to have grown to the size of an airplane hangar door, allowing almost any biotech to go public at astonishingly high valuations.

Ultragenyx Pharmaceutical  (NASDAQ: RARE  ) doubled on the day of its IPO and has continued to rise since. As you can probably guess from the ticker, Ultragenyx is developing drugs for orphan indications.

Dicerna Pharmaceuticals (NASDAQ: DRNA  ) tripled after its IPO. The biotech, which is also focused on rare diseases, pulled back a little since its first day of trading, but Dicerna still trades well above where it priced its IPO.

In the video below, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss the progression of biotech investors from large-cap biotechs to small-cap biotechs and, eventually, as they seek more risk, to companies that have just gone public.

Identifying hot picks before everyone else
While investors might be on to Ultragenyx and Dicerna, not every hyper-growth market is fully valued. The key is to find a small-cap "pure-play," and then watch as it grows in EXPLOSIVE lockstep with its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2875503, ~/Articles/ArticleHandler.aspx, 11/26/2014 10:06:48 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement